Q3 2017 EPS Estimates for Astrazeneca PLC Increased by Analyst (AZN)
Astrazeneca PLC (NYSE:AZN) – Analysts at Leerink Swann lifted their Q3 2017 earnings per share (EPS) estimates for shares of Astrazeneca PLC in a report issued on Monday. Leerink Swann analyst S. Fernandez now anticipates that the company will earn $0.60 per share for the quarter, up from their previous estimate of $0.54. Leerink Swann currently has a “Market Perform” rating and a $34.00 target price on the stock. Leerink Swann also issued estimates for Astrazeneca PLC’s FY2017 earnings at $2.07 EPS and FY2018 earnings at $1.84 EPS.
Other equities research analysts have also recently issued reports about the company. Argus reaffirmed a “buy” rating and issued a $35.00 target price on shares of Astrazeneca PLC in a report on Friday, September 1st. Investec raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. Natixis raised Astrazeneca PLC from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca PLC in a report on Friday, September 22nd. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Astrazeneca PLC presently has a consensus rating of “Hold” and a consensus target price of $35.10.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/24/q3-2017-eps-estimates-for-astrazeneca-plc-increased-by-analyst-azn.html.
Shares of Astrazeneca PLC (AZN) opened at 34.39 on Tuesday. The company has a 50-day moving average price of $33.53 and a 200-day moving average price of $32.43. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. The company has a market cap of $87.08 billion, a PE ratio of 22.56 and a beta of 0.76.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter in the prior year, the business earned $0.83 EPS. The firm’s revenue for the quarter was down 9.9% on a year-over-year basis.
A number of large investors have recently modified their holdings of the stock. Garrison Financial Corp raised its stake in Astrazeneca PLC by 0.5% in the second quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock worth $616,000 after buying an additional 86 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its stake in Astrazeneca PLC by 0.7% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company’s stock worth $454,000 after buying an additional 94 shares in the last quarter. NEXT Financial Group Inc raised its stake in Astrazeneca PLC by 1.8% in the second quarter. NEXT Financial Group Inc now owns 6,463 shares of the company’s stock worth $220,000 after buying an additional 115 shares in the last quarter. Atria Investments LLC raised its stake in Astrazeneca PLC by 0.5% in the second quarter. Atria Investments LLC now owns 24,695 shares of the company’s stock worth $842,000 after buying an additional 129 shares in the last quarter. Finally, Financial Counselors Inc. raised its stake in Astrazeneca PLC by 2.7% in the second quarter. Financial Counselors Inc. now owns 6,871 shares of the company’s stock worth $234,000 after buying an additional 182 shares in the last quarter. 14.18% of the stock is owned by institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.